Literature DB >> 15270784

Sex-differences in prevalence of electrocardiographic left ventricular hypertrophy in Type 2 diabetes: the Casale Monferrato Study.

G Bruno1, S Giunti, G Bargero, S Ferrero, G Pagano, P Cavallo Perin.   

Abstract

UNLABELLED: AIMS Although left ventricular hypertrophy (LVH) defined by either standard 12-lead ECG or echocardiography strongly predicts cardiovascular mortality, its prevalence in Type 2 diabetes is largely unknown. We have assessed prevalence of ECG-LVH and its relationship with clinical and metabolic variables in an Italian population-based cohort of subjects with Type 2 diabetes. METHODS The study-base was 965 (61.3%) subjects with Type 2 diabetes of the population-based cohort living in Casale Monferrato (Italy). LVH was defined by ECG Cornell voltage-duration product. All measurements were centralized. RESULTS ECG-LVH was diagnosed in 165/965 subjects, giving a prevalence of 17.1% (95% CI 14.7-19.5). Large sex differences were found, with higher prevalence in women (23.5%, 19.9-27.0) than in men (8.4%, 5.6-11.0), even after adjustment for age, BMI and hypertension (OR 3.83, 95% CI 2.5-5.9). At the examination, subjects with ECG-LVH were older than those without it. Similar age- and sex-adjusted values of HbA(1c), plasma lipids, fibrinogen, uric acid and creatinine were found in the two subgroups. No differences in prevalence of hypertension, CHD, increased QT duration or dispersion, micro- and macro-albuminuria were found between subjects with ECG-LVH and those without it. In logistic regression analysis, variables independently associated with ECG-LVH, after age-adjustment, were sex and diastolic blood pressure.
CONCLUSIONS: This population-based study shows: (i) a high prevalence of ECG-LVH in Type 2 diabetic subjects; (ii) 3-fold higher risk in women than in men, independently of age, BMI, and blood pressure; (iii) an independent association between ECG-LVH and diastolic blood-pressure. Screening for ECG-LVH in diabetic subjects is therefore recommended, particularly in diabetic women. Copyright 2004 Diabetes UK

Entities:  

Mesh:

Year:  2004        PMID: 15270784     DOI: 10.1111/j.1464-5491.2004.01246.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  9 in total

1.  Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

Authors:  G Boner; M E Cooper; K McCarroll; B M Brenner; D de Zeeuw; P R Kowey; S Shahinfar; T Dickson; R S Crow; H-H Parving
Journal:  Diabetologia       Date:  2005-08-05       Impact factor: 10.122

2.  Electrocardiographic Left Ventricular Hypertrophy Among Gambian Diabetes Mellitus Patients.

Authors:  M Jobe; A Kane; J C Jones; S Pessinaba; B C Nkum; S Abdou Ba; O A Nyan
Journal:  Ghana Med J       Date:  2015-03

Review 3.  Conundrum of pathogenesis of diabetic cardiomyopathy: role of vascular endothelial dysfunction, reactive oxygen species, and mitochondria.

Authors:  Mandip Joshi; Sainath R Kotha; Smitha Malireddy; Vaithinathan Selvaraju; Abhay R Satoskar; Alexender Palesty; David W McFadden; Narasimham L Parinandi; Nilanjana Maulik
Journal:  Mol Cell Biochem       Date:  2013-12-04       Impact factor: 3.396

4.  Screening for left ventricular hypertrophy in patients with type 2 diabetes mellitus in the community.

Authors:  Jithendra B Somaratne; Gillian A Whalley; Katrina K Poppe; Mariska M ter Bals; Gina Wadams; Ann Pearl; Warwick Bagg; Rob N Doughty
Journal:  Cardiovasc Diabetol       Date:  2011-04-14       Impact factor: 9.951

5.  Comparison of left ventricular mass in normotensive type 2 diabetes mellitus patients with that in the nondiabetic population.

Authors:  Sukamal Santra; Asish Kumar Basu; Pradip Roychowdhury; Ramtanu Banerjee; Pankaj Singhania; Sudhakar Singh; Utpal Kumar Datta
Journal:  J Cardiovasc Dis Res       Date:  2011-01

6.  Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study.

Authors:  Luis Cea-Calvo; Pedro Conthe; Pablo Gómez-Fernández; Fernando de Alvaro; Cristina Fernández-Pérez
Journal:  Cardiovasc Diabetol       Date:  2006-11-03       Impact factor: 9.951

7.  Cross-sectional analysis of serum calcium levels for associations with left ventricular hypertrophy in normocalcemia individuals with type 2 diabetes.

Authors:  Junfeng Li; Nan Wu; Yintao Li; Kuanping Ye; Min He; Renming Hu
Journal:  Cardiovasc Diabetol       Date:  2015-04-29       Impact factor: 9.951

8.  Risk factors for electrocardiographic left ventricular hypertrophy in a young Chinese general population: the Hanzhong adolescent cohort study.

Authors:  Yue-Yuan Liao; Ke Gao; Bo-Wen Fu; Lei Yang; Wen-Jing Zhu; Qiong Ma; Chao Chu; Yu Yan; Yang Wang; Wen-Ling Zheng; Jia-Wen Hu; Ke-Ke Wang; Yue Sun; Chen Chen; Jian-Jun Mu
Journal:  BMC Cardiovasc Disord       Date:  2021-03-31       Impact factor: 2.298

9.  Prevalence and covariates of electrocardiographic left ventricular hypertrophy in diabetic patients in Tanzania.

Authors:  J J K Lutale; H Thordarson; Z Gulam-Abbas; K Vetvik; E Gerdts
Journal:  Cardiovasc J Afr       Date:  2008 Jan-Feb       Impact factor: 1.167

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.